Bortezomib (trade name Velcade) is a boronic acid that was approved by the US Food and Drug Administration in 2003 as the first drug to treat multiple myeloma, a type of white blood cell cancer. It is a proteazome blocker that is also used to treat mantle cell lymphoma. Bortezomib passed US$1 million in sales in 2008. It has several adverse side effects, and current research is targeting improved proteazome inhibitors.
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.